Tapentadol in neuropathic pain cancer patients: a prospective open label study.

about

Tapentadol in neuropathic pain cancer patients: a prospective open label study.

Item

http://www.wikidata.org/entity/Q47324314

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Tapentadol in neuropathic pain cancer patients: a prospective open label study.

@en

Tapentadol in neuropathic pain cancer patients: a prospective open label study.

@nl

type

Item

label

Tapentadol in neuropathic pain cancer patients: a prospective open label study.

@en

Tapentadol in neuropathic pain cancer patients: a prospective open label study.

@nl

prefLabel

Tapentadol in neuropathic pain cancer patients: a prospective open label study.

@en

Tapentadol in neuropathic pain cancer patients: a prospective open label study.

@nl

P1476

Tapentadol in neuropathic pain cancer patients: a prospective open label study.

@en

P2093

Andrea Pace

http://www.w3.org/2001/XMLSchema#string

Edvina Galiè

http://www.w3.org/2001/XMLSchema#string

Irene Terrenato

http://www.w3.org/2001/XMLSchema#string

Veronica Villani

http://www.w3.org/2001/XMLSchema#string

P2860

Recommendations for the pharmacological management of neuropathic pain: an overview and literature update

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

Pharmacologic management of chronic pain.

EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.

The antinociceptive and antihyperalgesic effect of tapentadol is partially retained in OPRM1 (μ-opioid receptor) knockout mice.

Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review.

Pharmacology update: tapentadol for neuropathic pain.

Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.

Chemotherapy-induced neuropathy.

Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients

P2888

s10072-017-3035-1

P304

1747-1752

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10072-017-3035-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-07-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28699105

http://www.w3.org/2001/XMLSchema#string

P921

neuropathic pain